CLYYF OTC
Celyad Oncology S.A.
1W: +0.0%
1M: +0.0%
3M: +12.0%
YTD: +86.7%
1Y: -31.7%
3Y: -99.4%
$0.28
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$6M
+62.6% ▲
Capital Expenditures
$118K
+86.9% ▲
5Y CAGR: -28.3%
Free Cash Flow
-$6M
+64.7% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$3M
+48.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$17M | -$27M | -$41M | -$8M | -$6M |
| Depreciation & Amort. | $2M | $2M | $1M | $794K | $450K |
| Stock-Based Comp. | $3M | $2M | $2M | $935K | $0 |
| Change in Working Capital | -$3M | $1M | -$4M | -$1M | -$177K |
| Other Non-Cash Items | -$13M | -$5M | $14M | -$7M | -$129K |
| Operating Cash Flow | -$28M | -$27M | -$28M | -$15M | -$6M |
| — Investing Activities — | |||||
| Capital Expenditures | -$319K | -$393K | -$123K | -$934K | -$118K |
| Acquisitions (Net) | $235K | $0 | $6M | $0 | $15K |
| Investment Purchases | -$476K | $0 | $0 | $0 | $0 |
| Investment Sales | $241K | $0 | $1M | $0 | $0 |
| Other Investing | $476K | $267K | $235K | $1M | $0 |
| Investing Cash Flow | $157K | -$126K | $7M | $407K | -$103K |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1M | -$1M | -$896K | -$145K | -$167K |
| Stock Repurchased | $0 | $0 | -$124K | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $7M | $4M | $4M | $10K | $3M |
| Financing Cash Flow | $5M | $40M | $3M | $9M | $3M |
| Net Change in Cash | -$22M | $13M | -$18M | -$5M | -$3M |
| Cash End of Period | $17M | $30M | $12M | $7M | $4M |
| Free Cash Flow | -$28M | -$27M | -$28M | -$16M | -$6M |